PT - JOURNAL ARTICLE AU - Dafsari, Hormos Salimi AU - Deneubourg, Celine AU - Singh, Kritarth AU - Maroofian, Reza AU - Suprenant, Zita AU - Kho, Ay Lin AU - Ingham, Neil J AU - Steel, Karen P AU - Sheshadri, Preethi AU - Baur, Franciska AU - Hentrich, Lea AU - Gerisch, Birgit AU - Zamani, Mina AU - Alvares, Cesar AU - Siddiqui, Ata AU - Dafsari, Haidar S AU - Salari, Mehri AU - Lang, Anthony AU - Harris, Michael AU - Abdelaleem, Alice AU - Sadeghian, Saeid AU - Azizimalamiri, Reza AU - Galehdari, Hamid AU - Shariati, Gholamreza AU - Sedaghat, Alireza AU - Zeighami, Jawaher AU - Calame, Daniel AU - Marafi, Dana AU - Duan, Ruizhi AU - Boehnke, Adrian AU - Mohila, Carrie AU - Steel, Dora AU - Chopra, Saurabh AU - Sharma, Suvasini AU - Kohlschmidt, Nicolai AU - Patzer, Steffi AU - Saffari, Afshin AU - Ebrahimi-Fakhari, Darius AU - Eser Çavdartepe, Büşra AU - Chang, Irene J AU - Beckman, Erika AU - Peters, Renate AU - Fennell, Andrew Paul AU - Lo, Bernice AU - Averdunk, Luisa AU - Distelmaier, Felix AU - Baethmann, Martina AU - Elmslie, Frances AU - Joost, Kairit AU - Nampoothiri, Sheela AU - Yesodharan, Dhanya AU - Mandel, Hannah AU - Kimball, Amy AU - Kline, Antonie D. AU - Mignot, Cyril AU - Keren, Boris AU - Laugel, Vincent AU - Õunap, Katrin AU - Devadathan, Kalpana AU - van Berkestijn, Frederique M.C. AU - Silwal, Arpana AU - Koene, Saskia AU - Verma, Sumit AU - Karim, Mohammed Yousuf AU - Boubidi, Chahynez AU - Aziz, Majid AU - ElGhazali, Gehad AU - Mattas, Lauren AU - Miryounesi, Mohammad AU - Hashemi-Gorji, Farzad AU - Alavi, Shahryar AU - Nouri, Nayereh AU - Noruzinia, Mehrdad AU - Kavousi, Saeedeh AU - Kamath, Arveen AU - Jayawant, Sandeep AU - Saneto, Russell AU - Haridy, Nourelhoda A. AU - Kart, Pinar Ozkan AU - Cansu, Ali AU - Beneteau, Claire AU - Stuurman, Kyra E. AU - Wilke, Martina AU - Barakat, Tahsin Stefan AU - Tajsharghi, Homa AU - Scardamaglia, Annarita AU - Vallian, Sadeq AU - Hız, Semra AU - Shoeibi, Ali AU - Boostani, Reza AU - Hashemi, Narges AU - Babaei, Meisam AU - Alsaleh, Norah Saleh AU - Lander, Julie AU - Attié-Bitach, Tania AU - Marzin, Pauline AU - Wicher, Dorota AU - Gold, Jessica I AU - Monje, Mariana H G AU - Krainc, Dimitri AU - Mencacci, Niccolò AU - Bakhtiari, Somayeh AU - Kruer, Michael AU - Argilli, Emanuela AU - Sherr, Elliott AU - Jamshidi, Yalda AU - Karimiani, Ehsan Ghayoor AU - Cheung, Yiu Wing Sunny AU - Karin, Ivan AU - Chung, Wendy K AU - Lupski, James R. AU - Kurian, Manju A. AU - Dötsch, Jörg AU - von Kleist-Retzow, Jürgen-Christoph AU - Klopstock, Thomas AU - Wagner, Matias AU - Yip, Calvin AU - Roos, Andreas AU - Dionisi-Vici, Carlo AU - Gautel, Mathias AU - Duchen, Michael R AU - Antebi, Adam AU - Houlden, Henry AU - Fanto, Manolis AU - Jungbluth, Heinz TI - Mutations in EPG5 are associated with a wide spectrum of neurodevelopmental and neurodegenerative disorders AID - 10.1101/2024.06.12.24308722 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.12.24308722 4099 - http://medrxiv.org/content/early/2024/06/13/2024.06.12.24308722.short 4100 - http://medrxiv.org/content/early/2024/06/13/2024.06.12.24308722.full AB - Autophagy is a fundamental and evolutionary conserved biological pathway with vital roles in intracellular quality control and homeostasis. The process of autophagy involves the engulfment of intracellular targets by autophagosomes and their delivery to the lysosome for digestion and recycling. We have previously reported recessive variants in EPG5, encoding for the ectopic P-granules 5 autophagy protein with a crucial role in autophagosome-lysosome fusion, as the cause of Vici syndrome (VS), a severe multisystem neurodevelopmental disorder defined by a combination of distinct clinical features including callosal agenesis, cataracts, cardiomyopathy, immunodeficiency, and hypopigmentation. Here, we present extensive novel genetic, clinical, neuroradiological and pathological features from the largest cohort of EPG5-related disorders reported to date, complemented by experimental findings from patient cells and models of EPG5 defects in Caenorhabditis elegans and Mus musculus. We identified 200 patients with recessive EPG5 variants, 86 of them previously unpublished. The associated phenotypic spectrum ranged from antenatally lethal presentations and the classic VS phenotype (n=60) to much milder neurodevelopmental disorders with less specific manifestations (n=140). Myopathic features and epilepsy with variable progression were frequently observed. Novel manifestations included early-onset parkinsonism and dystonia with cognitive decline during adolescence, hereditary spastic paraplegia (HSPP), and myoclonus. Radiological findings included previously recognized EPG5-related features with callosal abnormalities and pontocerebellar hypoplasia, and a range of novel features suggesting an emerging continuum with disorders of brain iron accumulation or copper metabolism as well as HSPPs. Genotype-phenotype studies suggested a correlation between predicted residual EPG5 expression and clinical severity, especially regarding disease progression and survival. The Epg5 p.Gln331Arg knock-in mouse, a model of milder EPG5-related disorders, showed an age-related motor phenotype and impaired autophagic clearance in several brain regions mirroring those also affected in humans. In Caenorhabditis elegans, epg-5 knockdown gave rise to neurodevelopmental features and motor impairment comparable to defects in parkinsonism-related genes, abnormal mitochondrial respiration, and impaired mitophagic clearance early in life. Cellular assays revealed impaired PINK1-Parkin dependent mitophagic clearance in patient fibroblasts. Our findings expand the phenotypic spectrum of EPG5-related disorders and indicate a life time continuum of disease that overlaps with other disorders of defective autophagy and intracellular trafficking. Our observations also suggest close links between early-onset neurodevelopmental and neurodegenerative conditions of later onset due to EPG5 defects, in particular dystonia and parkinsonism, highlighting the fundamental importance of dysfunctional autophagy in the pathophysiology of common neurodegenerative disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the European Union Horizon 2020 Programme (765912 DRIVE H2020-MSCA-ITN-2017) to CD, MF and HJ, Action Medical Research (2446) to HJ and MF, and Action Medical Research (GN2959) to KS and MRD. HSD was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne (371/2021 and 243/2022), as well as the Cologne Clinician Scientist Program/Medical Faculty/University of Cologne and German Research Foundation (CCSP, DFG project No. 413543196). AA was supported by the Max Planck Gesellschaft. TSB was supported by the Netherlands Organisation for Scientific Research (ZonMw Vidi, grant 09150172110002), and acknowledges ongoing support from EpilepsieNL and CURE Epilepsy. KO is supported by Estonian Research Council grant PRG2040. Funding bodies did not have any influence on study design, results, and data interpretation or final manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Medical Faculty, University of Cologne gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.EPG5ectopic p granule protein 5VSVici syndromeMRImagnet resonance imaging